Lipoprotein-associated phospholipase A2 level in patients with Behçet's disease

Area of Science:

• Rheumatology and Immunology
• Vascular Inflammation Biomarkers

Background:

• Behçet's disease (BD) is a chronic inflammatory disorder characterized by vasculitis.
• Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a specific biomarker for vascular inflammation with low biological variability.
• Lp-PLA2 may offer advantages over non-specific markers like C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR).

Purpose of the Study:

• To investigate circulating Lp-PLA2 levels in Behçet's disease patients.
• To assess the relationship between Lp-PLA2, CRP, and ESR in BD.
• To evaluate Lp-PLA2 as a marker for disease activity in BD.

Main Methods:

• Study included 72 BD patients (40 active, 32 inactive) and 30 healthy controls.
• Measured serum levels of Lp-PLA2, CRP, and ESR.
• Analyzed correlations and diagnostic performance (AUC).

Main Results:

• Lp-PLA2, CRP, and ESR levels were significantly higher in BD patients compared to controls.
• Active BD patients exhibited higher levels of Lp-PLA2, CRP, and ESR than inactive patients.
• Lp-PLA2 positively correlated with CRP and ESR, showing a significant AUC of 0.779.

Conclusions:

• Lp-PLA2 may be a valuable biomarker for assessing clinical or subclinical activity in Behçet's disease.
• Lp-PLA2 shows potential alongside CRP and ESR for monitoring BD activity.
• Further research may establish Lp-PLA2 as a standard marker in BD management.